CX-904 is a conditionally activated T-cell-engaging bispecific designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. CX-904 uses CytomX’s Probody peptide-masking technology to reduce binding to EGFR and CD3 in normal tissues and direct binding towards tumor tissue.
Purpose: The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.
CX-2029 is a conditionally activated antibody-drug conjugate (Probody® therapeutic) employing the MMAE payload and targeting CD71, also known as the transferrin receptor 1. CX-2029 has a peptide-mask that is held in place by a protease-cleavable linker.
CX-2029 is currently being evaluated in a multi-cohort Phase 2 dose expansion study as monotherapy in patients with squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal or gastroesophageal junction cancer, or diffuse large B-cell lymphoma. CX-2029 is being developed in partnership with AbbVie.
Purpose: The purpose of this first-in-human study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-2029 in patients with one of four metastatic or locally advanced tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.